DrugPatentWatch Database Preview

TAVALISSE Drug Profile

« Back to Dashboard

When do Tavalisse patents expire, and what generic alternatives are available?

Tavalisse is a drug marketed by Rigel Pharms Inc and is included in one NDA. There are fourteen patents protecting this drug.

This drug has ninety-five patent family members in forty countries.

The generic ingredient in TAVALISSE is fostamatinib disodium. One supplier is listed for this compound. Additional details are available on the fostamatinib disodium profile page.

Summary for TAVALISSE

International Patents:	95
US Patents:	14
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	59
Patent Applications:	51
Drug Prices:	Drug price information for TAVALISSE
Prior Art and Litigation Support	Order Prior Art and Litigation support for TAVALISSE
DailyMed Link:	TAVALISSE at DailyMed

Generic Entry Opportunity Date for TAVALISSE

NDA:

209299

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for TAVALISSE

(6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl)methyl dihydrogen phosphate

(6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl dihydrogen phosphate

[6-({5-Fluoro-2-[(3,4,5-Trimethoxyphenyl)amino]pyrimidin-4-Yl}amino)-2,2-Dimethyl-3-Oxo-2,3-Dihydro-4h-Pyrido[3,2-B][1,4]oxazin-4-Yl]methyl Dihydrogen Phosphate

[6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxo-pyrido[3,2-b][1,4]oxazin-4-yl]methyl dihydrogen phosphate

[6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl dihydrogen phosphate

[6-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[2,3-e][1,4]oxazin-4-yl]methyl dihydrogen phosphate

2H-Pyrido(3,2-b)-1,4-oxazin-3(4H)-one, 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)-4-pyrimidinyl)amino)-2,2-dimethyl-4-((phosphonooxy)methyl)-

2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 6-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2-dimethyl-4-[(phosphonooxy)methyl]-

2RC

4CA-0549

6-((5-Fluoro-2-((3,4,5-trimethoxyphenyl)amino)-4-pyrimidinyl)amino)-2,2-dimethyl-4-((phosphonooxy)methyl)-2h-pyrido(3,2-b)-1,4-oxazi n-3(4h)-one

6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)-4-pyrimidinyl)amino)-2,2-dimethyl-4-((phosphonooxy)methyl)-2h-pyrido(3,2-b)-1,4-oxazin-3(4h)-one

6-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2-dimethyl-4-[(phosphonooxy)methyl]-2H-pyrido[3,2-b]-1,4-oxazin-3(4H)-one

901119-35-5

945745-48-2

AB0008135

ABP000970

AK174913

AKOS025404920

AM81257

AN-576

BCP9000704

BCPP000226

BDBM50431381

CHEMBL2103830

CS-2152

D09347

D0V8HJ

DB12010

EX-A108

Fostamatinib

Fostamatinib (R788)

Fostamatinib (USAN)

Fostamatinib [USAN:INN]

Fostamatinib(R788)

Fostamatinib/R788

FT-0699180

GKDRMWXFWHEQQT-UHFFFAOYSA-N

GTPL7796

HMS3651H09

HY-13038A

J-517972

KB-80322

KS-00000XGF

MFCD16628163

MolPort-021-804-956

NCGC00346622-01

PB25570

Q-4555

QCR-82

R 788

R-788

R-788 Free acid

R-935788

R-935788 Free acid

R788

R788 (Fostamatinib)

R7935788

RL05675

s2625

SC-47719

SCHEMBL1201371

SQ8A3S5101

UNII-SQ8A3S5101

VA12036

ZINC43131420

US Patents and Regulatory Information for TAVALISSE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rigel Pharms Inc	TAVALISSE	fostamatinib disodium	TABLET;ORAL	209299-002	Apr 17, 2018		RX	Yes	Yes
Rigel Pharms Inc	TAVALISSE	fostamatinib disodium	TABLET;ORAL	209299-002	Apr 17, 2018		RX	Yes	Yes			Y
Rigel Pharms Inc	TAVALISSE	fostamatinib disodium	TABLET;ORAL	209299-002	Apr 17, 2018		RX	Yes	Yes			Y
Rigel Pharms Inc	TAVALISSE	fostamatinib disodium	TABLET;ORAL	209299-001	Apr 17, 2018		RX	Yes	No

International Patents for TAVALISSE

Country	Patent Number	Estimated Expiration
Israel	183890
Uruguay	34223
Australia	2012288632
European Patent Office	2161275